Showing results (61-70 of 824) with videos related to

Sort By:
Pageof 83
Blood|September 18, 2012
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cellsZe Tian, Jian-jun Zhao, Yu-Tzu Tai, et al.
Cancer Research|October 20, 2004
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomibKlaus Podar, Reshma Shringarpure, Yu-Tzu Tai, et al.
Blood|May 31, 2002
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
Leukemia & Lymphoma|June 15, 2017
Overcoming multiple myeloma drug resistance in the era of cancer 'omics'Matthew Ho Zhi Guang, Amanda McCann, Giada Bianchi, et al.
Blood|October 1, 2008
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3Erik A Nelson, Sarah R Walker, Alicia Kepich, et al.
British Journal of Haematology|May 11, 2016
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patientsNancy Levin, Andrew Spencer, Simon J Harrison, et al.
Blood Advances|October 14, 2021
Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survivalTianzeng Chen, Matthew Ho, Jenna Briere, et al.
Cancer Management and Research|December 29, 2010
Bortezomib in the management of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Teru Hideshima, et al.
British Journal of Haematology|January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Blood|October 24, 2002
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Teru Hideshima, Constantine Mitsiades, Masaharu Akiyama, et al.
Pageof 83